Pandemic (H1N1) 2009-Associated ARDS Rescued by Neuraminidase Inhibitors with Emergency Use of Extracorporeal Membrane Oxygenation

Nakanishi, Hideyuki; Muta, Tsuyoshi; Fujisaki, Tomoaki; Yoshitomi, Ryota; Kubo, Toshihiko; Yokota, Eisuke

doi:10.2169/internalmedicine.49.3745

Cited by 4 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…None of the patients had severe disease and all were treated as outpatients. Severe adult influenza infection has been reportedly treated with peramivir [18]. Although oseltamivir and zanamivir are used for severe influenza infections such as encephalopathy [19], peramivir is more suitable for such infections because it is much easier to administer (intravenously) to a severe case when compared with oral oseltamivir or inhaled zanamivir.…”

Section: Discussionmentioning

confidence: 99%

Clinical Effectiveness of Peramivir in Comparison with Other Neuraminidase Inhibitors in Pediatric Influenza Patients

Hikita¹,

Hikita²,

Hikita³

et al. 2012

International Journal of Pediatrics

View full text Add to dashboard Cite

The currently used antivirals in the treatment of influenza in Japan include amantadine, oseltamivir, zanamivir, laninamivir, and peramivir. We compared the efficacy of intravenous peramivir with that of other neuraminidase inhibitors for treating pediatric influenza. The present study included 223 influenza patients (≤18 years) who presented at the Hikita Pediatric Clinic between February and April 2011. We compared fever duration after starting treatment with antiviral drugs. Because inhalation drugs are difficult to use in <5-year-old patients and because of the potential adverse effects of oseltamivir in teenagers, we created two different age groups (<10-year-old group and 5–18-year-old group) to evaluate treatment results. In influenza A patients between 5 and 18 years old, the median fever duration after treatment with zanamivir was 2 days, compared with 1 day for peramivir (P = 0.0242). In influenza B patients between 5 and 18 years old, the median fever duration after treatment with laninamivir was 3 days, compared with 1 day for peramivir (P = 0.0097). We found no significant difference for any of the other combinations of drug/disease type/age groups. No adverse effects were observed with the antiviral drugs used. The results suggest that peramivir is very useful in pediatric influenza patients.

show abstract

Section: Discussionmentioning

confidence: 99%